New aspects in the management of obesity: Operation and the impact of lipase inhibitors

Current Opinion in Lipidology

Volumn 10, Issue 1, 1999, Pages 3-7

  Uusitupa, Matti ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN;

CALORIC INTAKE; CALORIC RESTRICTION; FAT INTAKE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SHORT SURVEY; SLEEP APNEA SYNDROME; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; LACTONES; LIPASE; MULTICENTER STUDIES; OBESITY; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; WEIGHT LOSS;

EID: 0032966342     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199902000-00002     Document Type: Short Survey

References (25)

1. World Health Organisation. Obesity: preventing and managing the global epidemic. Geneva, 3-5 June 1997.
2. Grundy SM. Multifactorial causation of obesity: implications for prevention. Am JClin Nutr 1998; 57(suppl):563S-572S. A recent review of the causes and consequences for health of obesity.Furthermore, prevention measures at population level are discussed.
3. Flancbaum L, Choban SP. Surgical implications of obesity. Annu Rev Med 1998; 49:215-234. The authors give valuable information about the medical problems related to obesity and summarize the methods and results of surgical treatment of obesity.
4. Männistö S, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer 1996; 68:8-13.
5. Chagnon YC, Perusse L, Bouchard C. The human obesity gene map: the 1997 updates. Obes Res 1998; 6:76-92. A valuable summary of the challenging task. It is shown that no major breakthrough in the genetics of human obesity has been achieved thus far.
6. Editorial. Diet pills Redux. N Engl J Med 1997; 337:629-630.
7. Balsiger BM, Luque-deLeon E, Sarr MG. Surgical treatment of obesity: who isan appropriate candidate? Mayo Clin Proc 1997; 72:551-558. An excellent review of the methods, indications and complications of bariatricsurgery.
8. Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D et al. Biliopancreatic diversion. World J Surg 1998; 22:936-946. The authors summarize their own results on 2241 patients treated with biliopancreatic diversion. Interestingly, basal energy expenditure may not be reduced in women (as usually happens with weight loss) because of an increase in size and functional activity of whole intestinal tract.
9. Noya G, Cossu ML, Coppola M, Tonolo G, Angius MF, Fais E, Ruggiu M. Biliopancreatic diversion preserving the stomach and pylorus in the treatment ofhypercholesterolemia and diabetes II: results in the first 10 cases. Obesity Surg1998; 8:67-72. The authors report normalization of hypercholesterolaemia and glucose metabolism in type 2 diabetes after biliopancreatic diversion in a small group of moderately obese patients.
10. Mingrove G, Gaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M, Gasbarrini G. Reversibility of insulin resistance in obese diabetic patients: roleof plasma lipids. Diabetologia 1997; 40:599-605. A metabolic study that suggests that improvements in plasma free fatty acid and triglyceride levels could contribute to an improvement in whole body glucose uptake in obese individuals treated with biliopancreatic diversion operation.
11. Fobi MAL, Lee H, Holness R, DeGaulle Cabinda. Gastric bypass operation forobesity. World J Surg 1998; 22:925-935. The authors report the 2-year follow-up results on 516 obese subjects treated bygastric bypass. The success rate in terms of weight loss was 85%.
12. Cowan GSM, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg 1998; 22:987-992.
13. Sjöström CD, Lissner L, Sjöström L. Relationships between changes in bodycomposition and changes in cardiovascular risk factors: the SOS interventionstudy. Obesity Res 1997; 5:519-530. This ongoing study with a large number of Swedish obese subjects will provide important new information on the impact of marked weight loss on the future morbidity and mortality from causes related to severe obesity.
14. Weibel EK, Hadvary P, Hochuli E, Kupher E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. J Antibiotics 1987; 40:1081-1085.
15. Borgström B: Mode of action of tetrahydrolipstatin:a derivative of naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988; 962:308-316.
16. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988; 256:357-361.
17. Chadha NK, Batcho AD, Tang PC, Courtney LF, Cook CM, Wovkulich PM, Uskokovic MR. Synthesis of tetrahydrolipstatin. J Org Chem 1991; 56:4714-4718.
18. Hauptman JB, Jeunet FS, Hartman D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55:309S-313S.
19. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995; 19:221-226.
20. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21(suppl 3):S12-S23.
21. McNeely W, Benfield P. Orlistat. Drugs 1998; 56:241-249.
22. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M, for the European Multicentre Orlistat Study Group. Randomisedplacebo-controlled trial of orlistat for weight loss and prevention of weight regainin obese patients. Lancet 1998; 352:167-173. This 2-year controlled study with a large number of obese patients shows that orlistat, a pancreatic lipase inhibitor, results in clinically significant weight reduction and concomitant favourable changes in cardiovascular risk factors. The authors also suggested that orlistat may have an independent cholesterol-lowering effect.
23. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-yearrandomized double-blind study. Diabetes Care 1998; 21:1288-1294. The authors report the results on an initial number of 391 obese type 2 diabetic patients of whom 254 completed the 1-year trial. There was a moderate decrease in body weight with orlistat (net decrease compared with placebo 2.2 kg). Furthermore, serum total cholesterol, LDL cholesterol and metabolic control improved more in the orlistat group than in the placebo group. Orlistat had an independent cholesterol-lowering effect.
24. Reitsma JB, Cabezas MC, deBruin TWA, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43:293-298.
25. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA et al. The effect of gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidemia. Eur J Clin Pharmacol 1994; 46:405-410.